Search Results

World Single-Cell Day highlights the power of seeing biology one cell at a time. Single-cell analysis uncovers meaningful signals hidden within complex systems, enabling more precise insights into disease, development, and therapeutic response.

Roche has tapped Simcere Zaiming for a new T cell engager that could have broad application in B cell–mediated diseases including lymphoma and autoimmune conditions.

Registration’s open for the September 16 session. Buying ChatGPT or Claude Enterprise was the easy part. The hard questions start the day after. What data goes into the model? Who can see what? What happens to spend at 150 daily users? Can you show a regulator how a decision was made? And why are scientists still leaving the platform to do the actual science? We ran this session in August. The questions that came in beforehand told us more than our own agenda did. What does the latest FDA guidance say about agentic AI in a GxP environment? How do you compare the data-leakage risk of an enterprise assistant that reads all of your email and files against an employee pasting a document into a prompt? Neither of those is a question about what AI can do. They’re questions about control. And nobody asks them until after they’ve deployed. So we’re running it again, with more time on both. Beyond Claude & ChatGPT: AI Purpose Built for Biotech We’ll share what we’ve learned from real biotech AI deployments, then show one option that addresses these questions: Cortex. Data controls. Spend controls. Governed access to enterprise data. Auditability. And AI built for how scientists actually work. If your company has moved past “Should we use AI?” to “How do we govern, scale, and operationalize it?”, this session is for you. Wednesday, September 16 · 2:00 to 3:00 PM PT Register here: https://celitotech.com/ai-purpose-built-for-biotech/ #Biotech #AI #LifeSciences #GxP #Cortex